Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis

Fig. 3

Forest plots of PFS and OS: combination of pertuzumab with HER2 inhibitors versus HER2-targeted therapies without pertuzumab for patients with HER2+ breast cancer. PFS = progression free survival, OS = overall survival, HER2 = human epidermal growth factor receptor 2, HR = hazard ratio

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us